Acquired Athyrium Capital Management in Dec 2023
RVLP - RVL Pharmaceuticals plc
NASDAQ
->
Healthcare
->
Biotechnology
Bridgewater,
United States
Type: Equity
RVLP price evolution
RVLP
| (in millions $) | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.93 | $1.88 | $3.03 | $3.28 |
| Inventory | $1.36 | $0.21 | $0.78 | $0.62 |
| Total current assets | $25.75 | $38.35 | $56.98 | $70.91 |
| Long term investments | ||||
| Property, plant & equipment | $3.81 | $3.01 | $1.79 | $1.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $85.4 | $111.11 | $128.51 | $155.35 |
| Current liabilities | ||||
| Accounts payable | $2.53 | $2.63 | $2.41 | $7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $68.39 | $16.41 | $19.72 | $21.48 |
| Long term debt | $0.01 | $53.05 | $55.52 | $55.92 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $69.08 | $71.11 | $77.42 | $86.81 |
| Shareholders' equity | ||||
| Retained earnings | -$604.72 | -$580.83 | -$569.22 | -$550.9 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3.03 | $2.13 | $26.41 | $43.91 |
| Inventory | $0.78 | $0.84 | $17.93 | $21.3 |
| Total current assets | $56.98 | $59.38 | $173.15 | $172.63 |
| Long term investments | ||||
| Property, plant & equipment | $1.79 | $2.23 | $30.81 | $35.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $128.51 | $144.67 | $370.95 | $463.25 |
| Current liabilities | ||||
| Accounts payable | $2.41 | $3.78 | $6.77 | $8.49 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.72 | $20.11 | $55.78 | $75.94 |
| Long term debt | $55.52 | $43.8 | $219.53 | $267.99 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $77.42 | $67.94 | $277.09 | $348.55 |
| Shareholders' equity | ||||
| Retained earnings | -$569.22 | -$517.53 | -$452.61 | -$373.02 |
| Other shareholder equity | $1.7 | -$2.23 | -$2.23 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.26 | $8.83 | $9.81 | $10.02 |
| Cost of revenue | ||||
| Gross Profit | $6.31 | $6.53 | $7.25 | $7.5 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $14.43 | $16.82 | $18.48 | $20.42 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.11 | $0.06 | -$0.28 | $0.06 |
| Interest expense | -$3.16 | -$7.38 | -$1.92 | $3.93 |
| Net income | ||||
| Net income | -$23.89 | -$11.61 | -$18.32 | -$14.45 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $49.72 | $177.88 | $240.03 | |
| Cost of revenue | ||||
| Gross Profit | $40.27 | $103.4 | $128.4 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $83.04 | $101.66 | $125.35 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.02 | -$4.7 | -$27.12 | |
| Interest expense | -$0.25 | -$14.4 | -$18.21 | |
| Net income | ||||
| Net income | -$51.69 | -$79.59 | -$270.9 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.18 | -$1.23 | $0.13 | $0.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$5.32 | -$4.86 | $41.78 | $40.39 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$25.38 | -$11.9 | $4.1 | $19.31 |
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.13 | $116.45 | -$3.08 | -$4.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $41.78 | -$135.33 | $3.68 | -$4.69 |
| Effect of exchange rate | $0.17 | |||
| Change in cash and equivalents | $4.1 | -$73.61 | $18.19 | $25.03 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 99.39M |
| Revenue | $36.92M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$68.27M |
| Revenue Q/Q | -2.25% |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.69 |
|---|---|
| ROA | -56.84% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.38 |
| Quick ratio | 0.36 |